Form 4: Niagen Bioscience Exec Buys Shares
Statement of Changes in Beneficial Ownership
Robert N. Fried, CEO and Director of Niagen Bioscience, Inc., reported the acquisition of 1,106 shares of common stock on June 30, 2026.
Summary
- Robert N. Fried, Chief Executive Officer and Director of Niagen Bioscience, Inc. (NAGE), acquired 1,106 shares of common stock on June 30, 2026.
- The acquisition was made through the Issuer's Employee Stock Purchase Plan at a price of $2.71 per share.
- This transaction is exempt under Rule 16b-3(c) and 16b-3(d).
- Following this transaction, Fried beneficially owns 1,060,087 shares of common stock.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing due to the insider purchase, indicating management confidence, but it does not provide new financial or strategic information.
Positives
- Insider purchase of company stock by the CEO and Director, indicating confidence in the company's future.
- Acquisition made through an Employee Stock Purchase Plan, suggesting a structured and ongoing investment strategy.
Future Outlook
No specific forward-looking statements or guidance are provided in this Form 4 filing, which solely reports a change in beneficial ownership.
Industry Context
StockSavvy.ai notes that insider purchases, particularly by C-suite executives and directors, are often viewed positively by the market as they signal a belief in the company's intrinsic value and future prospects. This filing for Niagen Bioscience, Inc. aligns with this general observation.
Stakeholder Impact
- Shareholders may view the CEO's purchase as a positive signal of confidence in the company's future performance.
- Employees participating in the Employee Stock Purchase Plan are engaging in a structured way to invest in the company.
Key Dates
| Date | Description |
|---|---|
| 06/02/1999 | Date of Fried-Travis Revocable Trust U/A |
| 02/26/2020 | Date of The Jeremy W Fried 2020 Irrevocable Trust and The Benjamin A Fried 2020 Irrevocable Trust |
| 06/30/2026 | Transaction Date for acquisition of common stock |
| 07/08/2026 | Date of signature for the filing |
Recommendation
holdThis filing is a routine disclosure of insider stock acquisition and does not contain material information that would warrant a change in investment strategy. The purchase by the CEO is a positive signal but does not provide sufficient new data for a strong buy or sell recommendation.
Keywords
Form 4, SEC Filing, Insider Trading, Niagen Bioscience, NAGE, Stock Purchase, CEO, Director, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.